Background
What it is, how it developed and why it is discussed
KPV is the C-terminal tripeptide Lys-Pro-Val from alpha-melanocyte-stimulating hormone. Laboratory and animal research has explored anti-inflammatory signalling, but clinical evidence is limited.
Evidence
Evidence, limitations and clinical context
A registered human-use product and its South African scheduling must be verified before sale.
Clinical access
Availability requires regulatory confirmation
Online purchase remains disabled until the exact human-use product, South African registration and scheduling have been verified. A clinical assessment can still be booked to discuss appropriate options.
Clinical assessment Clinician authorisation
